Acorda Therapeutics (ACOR) Misses Q1 EPS by 16c

Acorda Therapeutics (NASDAQ: ACOR) reported Q1 EPS of ($0.51), $0.16 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $28 million versus the consensus estimate of $41.01 million.

2020 Financial Guidance:

For the full-year 2020, Acorda continues to expect AMPYRA net revenue to be $85 - $110 million, and operating expenses to be $170 - $180 million. The operating expense guidance is a non-GAAP projection that excludes restructuring costs and share-based compensation as more fully described below under “Non-GAAP Financial Measures.”

As a result of declines in physician office visits due to COVID-19 stay-at-home orders, the Company is withdrawing its previously announced 2020 INBRIJA net revenue guidance. This also necessitates the withdrawal of 2020 total net product revenue. Acorda continues to expect INBRIJA peak sales to be $300 - $500 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• The Gap, Inc. (GAP) Tops Q2 EPS by 3c
• Workday (WDAY) Tops Q2 EPS by 14c; offers outlook
• Titan Machinery (TITN) Misses Q2 EPS by 5c ; Offers Guidance